

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known.

Application Number	09/854,142
Filing Date	May 10, 2001
First Named Inventor	Ilse Bartk
Group Art Unit	1651
Examiner Name	Jon P. Weber
Attorney Docket Number	305J-900320US
Date Submitted	December 23, 2003

U.S. PATENT DOCUMENTS


Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JW	01	Barde et al. (1980) Sensory neurons in culture: changing requirements for survival factors during embryonic development. Proc. Natl. Acad. Sci. USA. 77:1199-1203	
JW	02	Bothwell (1995) Functional interactions of neurotrophins and neurotrophin receptors. Annu. Rev. Neurosci. 18:223-253	
JW	03	Cannella et al. (1998) The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc. Natl. Acad. Sci. USA. 95:10100-10105	
JW	04	Carter et al. (1997) Neurotrophins live or let die: does p75NTR decide? Neuron. 18: 187-190	
JW	05	Charlton et al. (1995) The Th1/Th2 balance in autoimmunity. Curr. Opin. Immunol. 7:793-798	
JW	06	De Simone et al. (1996) mRNA for NGF and p75 in the central nervous system of rats affected by experimental allergic encephalomyelitis. Neuropathol. Appl. Neurobiol. 22:54-59	
JW	07	Dugan, et al. (1997) Rapid suppression of free radical formation by nerve growth factor involves the mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA. 94:4086-4091	
JW	08	Flierz, et al. (1985) Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J. Immunol. 134:3785-3793	
JW	09	Gadient et al. (1990) Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neurosci. Lett. 117:335-340	

Examiner Signature		Date Considered	06 Feb 04
-----------------------	---	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO


INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/854,142
Filing Date	May 10, 2001
First Named Inventor	Ils Bartke
Group Art Unit	1651
Examiner Name	Jon P. Weber
Attorney Docket Number	305J-900320US
Date Submitted	December 23, 2003

10	Genain et al. (1995) Antibody facilitation of multiple sclerosis-like lesions in a non human primate. J. Clin. Invest. 96:2966-2974
11	Genain et al. (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:170-175
12	Hohlfeld (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain. 120:865-916
13	Kossmann et al. (1996) Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Res. 713:143-152
14	Kramer et al. (1995) Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat. Med. 1:1162-1166
15	Levi-Montalcini et al (1996) Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 19:514-520
16	Lewin et al. (1996) Physiology of the neurotrophins. Annu. Rev. Neurosci. 19:289-317
17	Lovett-Racke et al. (1998) Regulation of experimental allergic encephalomyelitis with insulin growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF/IGFBP3). J. Clin. Invest. 101: 1797-1804
18	Neumann, et al. (1998) Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc. Natl. Acad. Sci. USA. 95:5779-5784
19	Raine (1997) Demyelinating diseases. In Davis R., Robertson., Eds. Textbook of Neuropathology. 3 rd ed. Baltimore, Williams & Wilkins, pp. 627-714.
20	Steinman, (2000) Multiple approaches to multiple sclerosis. Nat. Med. 6:15-16
21	Trapp, et al. (1998) Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:278-285
22	Urschel et al (1990) Schwann cell-neuronal interactions in the rat involve nerve growth factor. J. Comp. Neurol. 296:114-122
23	Villoslada et al. (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med., 191(10): 1799-1806
24	Williams, et al. (1996) IL-10 production by adult human derived microglial cells. Neurochem. Int. 29:55-64

Examiner Signature		Date Considered	06 Feb 04
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.